Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
Crossref DOI link: https://doi.org/10.1007/s00415-016-8341-7
Published Online: 2016-11-25
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schwartzbach, Caryl J.
Grove, Richard A.
Brown, Robert
Tompson, Debra
Then Bergh, Florian
Arnold, Douglas L.
Funding for this research was provided by:
GlaxoSmithKline
License valid from 2016-11-25